Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease
Identifieur interne : 001248 ( Istex/Corpus ); précédent : 001247; suivant : 001249Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease
Auteurs : Montse Alegret ; Francesc Valldeoriola ; Majosé Martí ; Manuela Pilleri ; Carme Junqué ; Jordi Rumià ; Eduardo TolosaSource :
- Movement Disorders [ 0885-3185 ] ; 2004-12.
English descriptors
- KwdEn :
Abstract
Bilateral subthalamic deep brain stimulation (STN‐DBS) and continuous subcutaneous infusion of apomorphine (APM‐csi) can provide a comparable improvement on motor function in patients with advanced Parkinson's disease (PD), but the mechanisms by which both therapies exert their effects are different. We analyzed the cognitive effects of APM‐csi. We also compared neuropsychological effects induced by STN‐DBS and APM‐csi in advanced PD to ascertain the neuropsychological aspects relevant in determining the therapeutic procedure that is the most appropriate in a particular patient. We studied 9 patients treated with STN‐DBS and 7 patients with APM‐csi. Neuropsychological measures included Rey's Auditory‐Verbal Learning, Stroop, Trail Making, phonetic verbal fluency, and Judgment of Line Orientation tests. In the APM‐csi group, significant changes were not observed in the neuropsychological tests performance. By contrast, in the STN‐DBS group, moderate worsening was found in phonetic verbal fluency and Stroop Naming scores that was partially reversible at long‐term follow‐up and did not have consequences on regular activities. Consequently, these findings could be interpreted as being not relevant in deciding the most suitable treatment in a given patient. © 2004 Movement Disorder Society
Url:
DOI: 10.1002/mds.20237
Links to Exploration step
ISTEX:A4291B57194D36B638D5FCE9EFD0C151E0450713Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease</title><author><name sortKey="Alegret, Montse" sort="Alegret, Montse" uniqKey="Alegret M" first="Montse" last="Alegret">Montse Alegret</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Valldeoriola, Francesc" sort="Valldeoriola, Francesc" uniqKey="Valldeoriola F" first="Francesc" last="Valldeoriola">Francesc Valldeoriola</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Marti, Majose" sort="Marti, Majose" uniqKey="Marti M" first="Majosé" last="Martí">Majosé Martí</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Pilleri, Manuela" sort="Pilleri, Manuela" uniqKey="Pilleri M" first="Manuela" last="Pilleri">Manuela Pilleri</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Junque, Carme" sort="Junque, Carme" uniqKey="Junque C" first="Carme" last="Junqué">Carme Junqué</name><affiliation><mods:affiliation>Department of Psychiatry and Clinical Psychobiology, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Rumia, Jordi" sort="Rumia, Jordi" uniqKey="Rumia J" first="Jordi" last="Rumià">Jordi Rumià</name><affiliation><mods:affiliation>Service of Neurosurgery, Institut de Malalties del Sistema Nerviós, Hospital Clínic, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:A4291B57194D36B638D5FCE9EFD0C151E0450713</idno><date when="2004" year="2004">2004</date><idno type="doi">10.1002/mds.20237</idno><idno type="url">https://api.istex.fr/document/A4291B57194D36B638D5FCE9EFD0C151E0450713/fulltext/pdf</idno><idno type="wicri:Area/Istex/Corpus">001248</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease</title><author><name sortKey="Alegret, Montse" sort="Alegret, Montse" uniqKey="Alegret M" first="Montse" last="Alegret">Montse Alegret</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Valldeoriola, Francesc" sort="Valldeoriola, Francesc" uniqKey="Valldeoriola F" first="Francesc" last="Valldeoriola">Francesc Valldeoriola</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Marti, Majose" sort="Marti, Majose" uniqKey="Marti M" first="Majosé" last="Martí">Majosé Martí</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Pilleri, Manuela" sort="Pilleri, Manuela" uniqKey="Pilleri M" first="Manuela" last="Pilleri">Manuela Pilleri</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Junque, Carme" sort="Junque, Carme" uniqKey="Junque C" first="Carme" last="Junqué">Carme Junqué</name><affiliation><mods:affiliation>Department of Psychiatry and Clinical Psychobiology, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Rumia, Jordi" sort="Rumia, Jordi" uniqKey="Rumia J" first="Jordi" last="Rumià">Jordi Rumià</name><affiliation><mods:affiliation>Service of Neurosurgery, Institut de Malalties del Sistema Nerviós, Hospital Clínic, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author><author><name sortKey="Tolosa, Eduardo" sort="Tolosa, Eduardo" uniqKey="Tolosa E" first="Eduardo" last="Tolosa">Eduardo Tolosa</name><affiliation><mods:affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</mods:affiliation></affiliation></author></analytic><monogr></monogr><series><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="ISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-12">2004-12</date><biblScope unit="vol">19</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1463">1463</biblScope><biblScope unit="page" to="1469">1469</biblScope></imprint><idno type="ISSN">0885-3185</idno></series><idno type="istex">A4291B57194D36B638D5FCE9EFD0C151E0450713</idno><idno type="DOI">10.1002/mds.20237</idno><idno type="ArticleID">MDS20237</idno></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">0885-3185</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="KwdEn" xml:lang="en"><term>Parkinson's disease</term><term>bilateral subthalamic deep brain stimulation</term><term>cognition</term><term>continuous subcutaneous infusion of apomorphine</term><term>prefrontal functions</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Bilateral subthalamic deep brain stimulation (STN‐DBS) and continuous subcutaneous infusion of apomorphine (APM‐csi) can provide a comparable improvement on motor function in patients with advanced Parkinson's disease (PD), but the mechanisms by which both therapies exert their effects are different. We analyzed the cognitive effects of APM‐csi. We also compared neuropsychological effects induced by STN‐DBS and APM‐csi in advanced PD to ascertain the neuropsychological aspects relevant in determining the therapeutic procedure that is the most appropriate in a particular patient. We studied 9 patients treated with STN‐DBS and 7 patients with APM‐csi. Neuropsychological measures included Rey's Auditory‐Verbal Learning, Stroop, Trail Making, phonetic verbal fluency, and Judgment of Line Orientation tests. In the APM‐csi group, significant changes were not observed in the neuropsychological tests performance. By contrast, in the STN‐DBS group, moderate worsening was found in phonetic verbal fluency and Stroop Naming scores that was partially reversible at long‐term follow‐up and did not have consequences on regular activities. Consequently, these findings could be interpreted as being not relevant in deciding the most suitable treatment in a given patient. © 2004 Movement Disorder Society</div></front></TEI><istex><corpusName>wiley</corpusName><author><json:item><name>Montse Alegret PhD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>Francesc Valldeoriola MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>MaJosé Martí MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>Manuela Pilleri MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>Carme Junqué PhD</name><affiliations><json:string>Department of Psychiatry and Clinical Psychobiology, IDIBAPS, University of Barcelona, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>Jordi Rumià MD</name><affiliations><json:string>Service of Neurosurgery, Institut de Malalties del Sistema Nerviós, Hospital Clínic, University of Barcelona, Barcelona, Spain</json:string></affiliations></json:item><json:item><name>Eduardo Tolosa MD</name><affiliations><json:string>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</json:string></affiliations></json:item></author><subject><json:item><lang><json:string>eng</json:string></lang><value>Parkinson's disease</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>bilateral subthalamic deep brain stimulation</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>continuous subcutaneous infusion of apomorphine</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>cognition</value></json:item><json:item><lang><json:string>eng</json:string></lang><value>prefrontal functions</value></json:item></subject><language><json:string>eng</json:string></language><abstract>Bilateral subthalamic deep brain stimulation (STN‐DBS) and continuous subcutaneous infusion of apomorphine (APM‐csi) can provide a comparable improvement on motor function in patients with advanced Parkinson's disease (PD), but the mechanisms by which both therapies exert their effects are different. We analyzed the cognitive effects of APM‐csi. We also compared neuropsychological effects induced by STN‐DBS and APM‐csi in advanced PD to ascertain the neuropsychological aspects relevant in determining the therapeutic procedure that is the most appropriate in a particular patient. We studied 9 patients treated with STN‐DBS and 7 patients with APM‐csi. Neuropsychological measures included Rey's Auditory‐Verbal Learning, Stroop, Trail Making, phonetic verbal fluency, and Judgment of Line Orientation tests. In the APM‐csi group, significant changes were not observed in the neuropsychological tests performance. By contrast, in the STN‐DBS group, moderate worsening was found in phonetic verbal fluency and Stroop Naming scores that was partially reversible at long‐term follow‐up and did not have consequences on regular activities. Consequently, these findings could be interpreted as being not relevant in deciding the most suitable treatment in a given patient. © 2004 Movement Disorder Society</abstract><qualityIndicators><score>6.437</score><pdfVersion>1.3</pdfVersion><pdfPageSize>594 x 792 pts</pdfPageSize><refBibsNative>true</refBibsNative><abstractCharCount>1305</abstractCharCount><pdfWordCount>4253</pdfWordCount><pdfCharCount>28648</pdfCharCount><pdfPageCount>7</pdfPageCount><abstractWordCount>182</abstractWordCount></qualityIndicators><title>Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease</title><genre><json:string>Serial article</json:string></genre><host><volume>19</volume><pages><total>7</total><last>1469</last><first>1463</first></pages><issn><json:string>0885-3185</json:string></issn><issue>12</issue><subject><json:item><value>Brief Report</value></json:item></subject><genre></genre><language><json:string>unknown</json:string></language><title>Movement Disorders</title><doi><json:string>10.1002/(ISSN)1531-8257</json:string></doi></host><publicationDate>2004</publicationDate><copyrightDate>2004</copyrightDate><doi><json:string>10.1002/mds.20237</json:string></doi><id>A4291B57194D36B638D5FCE9EFD0C151E0450713</id><fulltext><json:item><original>true</original><mimetype>application/pdf</mimetype><extension>pdf</extension><uri>https://api.istex.fr/document/A4291B57194D36B638D5FCE9EFD0C151E0450713/fulltext/pdf</uri></json:item><json:item><original>false</original><mimetype>application/zip</mimetype><extension>zip</extension><uri>https://api.istex.fr/document/A4291B57194D36B638D5FCE9EFD0C151E0450713/fulltext/zip</uri></json:item><istex:fulltextTEI uri="https://api.istex.fr/document/A4291B57194D36B638D5FCE9EFD0C151E0450713/fulltext/tei"><teiHeader type="text"><fileDesc><titleStmt><title level="a" type="main" xml:lang="en">Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease</title></titleStmt><publicationStmt><authority>ISTEX</authority><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><availability><p>Wiley Subscription Services, Inc., A Wiley Company</p></availability><date>2004</date></publicationStmt><notesStmt><note>Generalitat de Catalunya, Barcelona, Spain - No. 2001SGR00387;</note><note>European Neurological Society</note></notesStmt><sourceDesc><biblStruct type="inbook"><analytic><title level="a" type="main" xml:lang="en">Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease</title><author><persName><forename type="first">Montse</forename><surname>Alegret</surname><roleName type="degree">PhD</roleName></persName><affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation></author><author><persName><forename type="first">Francesc</forename><surname>Valldeoriola</surname><roleName type="degree">MD</roleName></persName><note type="correspondence"><p>Correspondence: Service of Neurology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain</p></note><affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation></author><author><persName><forename type="first">MaJosé</forename><surname>Martí</surname><roleName type="degree">MD</roleName></persName><affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation></author><author><persName><forename type="first">Manuela</forename><surname>Pilleri</surname><roleName type="degree">MD</roleName></persName><affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation></author><author><persName><forename type="first">Carme</forename><surname>Junqué</surname><roleName type="degree">PhD</roleName></persName><affiliation>Department of Psychiatry and Clinical Psychobiology, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation></author><author><persName><forename type="first">Jordi</forename><surname>Rumià</surname><roleName type="degree">MD</roleName></persName><affiliation>Service of Neurosurgery, Institut de Malalties del Sistema Nerviós, Hospital Clínic, University of Barcelona, Barcelona, Spain</affiliation></author><author><persName><forename type="first">Eduardo</forename><surname>Tolosa</surname><roleName type="degree">MD</roleName></persName><affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation></author></analytic><monogr><title level="j">Movement Disorders</title><title level="j" type="abbrev">Mov. Disord.</title><idno type="pISSN">0885-3185</idno><idno type="eISSN">1531-8257</idno><idno type="DOI">10.1002/(ISSN)1531-8257</idno><imprint><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><pubPlace>Hoboken</pubPlace><date type="published" when="2004-12"></date><biblScope unit="vol">19</biblScope><biblScope unit="issue">12</biblScope><biblScope unit="page" from="1463">1463</biblScope><biblScope unit="page" to="1469">1469</biblScope></imprint></monogr><idno type="istex">A4291B57194D36B638D5FCE9EFD0C151E0450713</idno><idno type="DOI">10.1002/mds.20237</idno><idno type="ArticleID">MDS20237</idno></biblStruct></sourceDesc></fileDesc><profileDesc><creation><date>2004</date></creation><langUsage><language ident="en">en</language></langUsage><abstract xml:lang="en"><p>Bilateral subthalamic deep brain stimulation (STN‐DBS) and continuous subcutaneous infusion of apomorphine (APM‐csi) can provide a comparable improvement on motor function in patients with advanced Parkinson's disease (PD), but the mechanisms by which both therapies exert their effects are different. We analyzed the cognitive effects of APM‐csi. We also compared neuropsychological effects induced by STN‐DBS and APM‐csi in advanced PD to ascertain the neuropsychological aspects relevant in determining the therapeutic procedure that is the most appropriate in a particular patient. We studied 9 patients treated with STN‐DBS and 7 patients with APM‐csi. Neuropsychological measures included Rey's Auditory‐Verbal Learning, Stroop, Trail Making, phonetic verbal fluency, and Judgment of Line Orientation tests. In the APM‐csi group, significant changes were not observed in the neuropsychological tests performance. By contrast, in the STN‐DBS group, moderate worsening was found in phonetic verbal fluency and Stroop Naming scores that was partially reversible at long‐term follow‐up and did not have consequences on regular activities. Consequently, these findings could be interpreted as being not relevant in deciding the most suitable treatment in a given patient. © 2004 Movement Disorder Society</p></abstract><textClass xml:lang="en"><keywords scheme="keyword"><list><head>Keywords</head><item><term>Parkinson's disease</term></item><item><term>bilateral subthalamic deep brain stimulation</term></item><item><term>continuous subcutaneous infusion of apomorphine</term></item><item><term>cognition</term></item><item><term>prefrontal functions</term></item></list></keywords></textClass><textClass><keywords scheme="Journal Subject"><list><head>Article category</head><item><term>Brief Report</term></item></list></keywords></textClass></profileDesc><revisionDesc><change when="2003-10-28">Received</change><change when="2004-03-16">Registration</change><change when="2004-12">Published</change></revisionDesc></teiHeader></istex:fulltextTEI><json:item><original>false</original><mimetype>text/plain</mimetype><extension>txt</extension><uri>https://api.istex.fr/document/A4291B57194D36B638D5FCE9EFD0C151E0450713/fulltext/txt</uri></json:item></fulltext><metadata><istex:metadataXml wicri:clean="Wiley, elements deleted: body"><istex:xmlDeclaration>version="1.0" encoding="UTF-8" standalone="yes"</istex:xmlDeclaration><istex:document><component version="2.0" type="serialArticle" xml:lang="en"><header><publicationMeta level="product"><publisherInfo><publisherName>Wiley Subscription Services, Inc., A Wiley Company</publisherName><publisherLoc>Hoboken</publisherLoc></publisherInfo><doi registered="yes">10.1002/(ISSN)1531-8257</doi><issn type="print">0885-3185</issn><issn type="electronic">1531-8257</issn><idGroup><id type="product" value="MDS"></id></idGroup><titleGroup><title type="main" xml:lang="en" sort="MOVEMENT DISORDERS">Movement Disorders</title><title type="short">Mov. Disord.</title></titleGroup></publicationMeta><publicationMeta level="part" position="120"><doi origin="wiley" registered="yes">10.1002/mds.v19:12</doi><numberingGroup><numbering type="journalVolume" number="19">19</numbering><numbering type="journalIssue">12</numbering></numberingGroup><coverDate startDate="2004-12">December 2004</coverDate></publicationMeta><publicationMeta level="unit" type="article" position="130" status="forIssue"><doi origin="wiley" registered="yes">10.1002/mds.20237</doi><idGroup><id type="unit" value="MDS20237"></id></idGroup><countGroup><count type="pageTotal" number="7"></count></countGroup><titleGroup><title type="articleCategory">Brief Report</title><title type="tocHeading1">Brief Reports</title></titleGroup><copyright ownership="thirdParty">Copyright © 2004 Movement Disorder Society</copyright><eventGroup><event type="manuscriptReceived" date="2003-10-28"></event><event type="manuscriptRevised" date="2004-03-09"></event><event type="manuscriptAccepted" date="2004-03-16"></event><event type="firstOnline" date="2004-07-09"></event><event type="publishedOnlineFinalForm" date="2004-10-27"></event><event type="publishedOnlineAcceptedOrEarlyUnpaginated" date="2004-07-09"></event><event type="xmlConverted" agent="Converter:JWSART34_TO_WML3G version:2.4.7 mode:FullText source:FullText result:FullText" date="2011-02-24"></event><event type="xmlConverted" agent="Converter:WILEY_ML3G_TO_WILEY_ML3GV2 version:3.8.8" date="2014-02-02"></event><event type="xmlConverted" agent="Converter:WML3G_To_WML3G version:4.1.7 mode:FullText,remove_FC" date="2014-10-31"></event></eventGroup><numberingGroup><numbering type="pageFirst">1463</numbering><numbering type="pageLast">1469</numbering></numberingGroup><correspondenceTo>Service of Neurology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain</correspondenceTo><linkGroup><link type="toTypesetVersion" href="file:MDS.MDS20237.pdf"></link></linkGroup></publicationMeta><contentMeta><countGroup><count type="figureTotal" number="1"></count><count type="tableTotal" number="2"></count><count type="referenceTotal" number="39"></count><count type="wordTotal" number="4442"></count></countGroup><titleGroup><title type="main" xml:lang="en">Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease</title><title type="short" xml:lang="en">Cognitive Effect of STN‐DBS and APO‐CSI in PD</title></titleGroup><creators><creator xml:id="au1" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Montse</givenNames><familyName>Alegret</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au2" creatorRole="author" affiliationRef="#af1" corresponding="yes"><personName><givenNames>Francesc</givenNames><familyName>Valldeoriola</familyName><degrees>MD</degrees></personName><contactDetails><email>fvallde@clinic.ub.es</email></contactDetails></creator><creator xml:id="au3" creatorRole="author" affiliationRef="#af1"><personName><givenNames>MaJosé</givenNames><familyName>Martí</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au4" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Manuela</givenNames><familyName>Pilleri</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au5" creatorRole="author" affiliationRef="#af2"><personName><givenNames>Carme</givenNames><familyName>Junqué</familyName><degrees>PhD</degrees></personName></creator><creator xml:id="au6" creatorRole="author" affiliationRef="#af3"><personName><givenNames>Jordi</givenNames><familyName>Rumià</familyName><degrees>MD</degrees></personName></creator><creator xml:id="au7" creatorRole="author" affiliationRef="#af1"><personName><givenNames>Eduardo</givenNames><familyName>Tolosa</familyName><degrees>MD</degrees></personName></creator></creators><affiliationGroup><affiliation xml:id="af1" countryCode="ES" type="organization"><unparsedAffiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af2" countryCode="ES" type="organization"><unparsedAffiliation>Department of Psychiatry and Clinical Psychobiology, IDIBAPS, University of Barcelona, Barcelona, Spain</unparsedAffiliation></affiliation><affiliation xml:id="af3" countryCode="ES" type="organization"><unparsedAffiliation>Service of Neurosurgery, Institut de Malalties del Sistema Nerviós, Hospital Clínic, University of Barcelona, Barcelona, Spain</unparsedAffiliation></affiliation></affiliationGroup><keywordGroup xml:lang="en" type="author"><keyword xml:id="kwd1">Parkinson's disease</keyword><keyword xml:id="kwd2">bilateral subthalamic deep brain stimulation</keyword><keyword xml:id="kwd3">continuous subcutaneous infusion of apomorphine</keyword><keyword xml:id="kwd4">cognition</keyword><keyword xml:id="kwd5">prefrontal functions</keyword></keywordGroup><fundingInfo><fundingAgency>Generalitat de Catalunya, Barcelona, Spain</fundingAgency><fundingNumber>2001SGR00387</fundingNumber></fundingInfo><fundingInfo><fundingAgency>European Neurological Society</fundingAgency></fundingInfo><abstractGroup><abstract type="main" xml:lang="en"><title type="main">Abstract</title><p>Bilateral subthalamic deep brain stimulation (STN‐DBS) and continuous subcutaneous infusion of apomorphine (APM‐csi) can provide a comparable improvement on motor function in patients with advanced Parkinson's disease (PD), but the mechanisms by which both therapies exert their effects are different. We analyzed the cognitive effects of APM‐csi. We also compared neuropsychological effects induced by STN‐DBS and APM‐csi in advanced PD to ascertain the neuropsychological aspects relevant in determining the therapeutic procedure that is the most appropriate in a particular patient. We studied 9 patients treated with STN‐DBS and 7 patients with APM‐csi. Neuropsychological measures included Rey's Auditory‐Verbal Learning, Stroop, Trail Making, phonetic verbal fluency, and Judgment of Line Orientation tests. In the APM‐csi group, significant changes were not observed in the neuropsychological tests performance. By contrast, in the STN‐DBS group, moderate worsening was found in phonetic verbal fluency and Stroop Naming scores that was partially reversible at long‐term follow‐up and did not have consequences on regular activities. Consequently, these findings could be interpreted as being not relevant in deciding the most suitable treatment in a given patient. © 2004 Movement Disorder Society</p></abstract></abstractGroup></contentMeta></header></component></istex:document></istex:metadataXml><!--Version 0.6 générée le 3-12-2015--><mods version="3.6"><titleInfo lang="en"><title>Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease</title></titleInfo><titleInfo type="abbreviated" lang="en"><title>Cognitive Effect of STN‐DBS and APO‐CSI in PD</title></titleInfo><titleInfo type="alternative" contentType="CDATA" lang="en"><title>Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease</title></titleInfo><name type="personal"><namePart type="given">Montse</namePart><namePart type="family">Alegret</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Francesc</namePart><namePart type="family">Valldeoriola</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation><description>Correspondence: Service of Neurology, Hospital Clínic, Villarroel 170, 08036 Barcelona, Spain</description><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">MaJosé</namePart><namePart type="family">Martí</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Manuela</namePart><namePart type="family">Pilleri</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Carme</namePart><namePart type="family">Junqué</namePart><namePart type="termsOfAddress">PhD</namePart><affiliation>Department of Psychiatry and Clinical Psychobiology, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Jordi</namePart><namePart type="family">Rumià</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Service of Neurosurgery, Institut de Malalties del Sistema Nerviós, Hospital Clínic, University of Barcelona, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><name type="personal"><namePart type="given">Eduardo</namePart><namePart type="family">Tolosa</namePart><namePart type="termsOfAddress">MD</namePart><affiliation>Parkinson's Disease and Movement Disorders Unit, Service of Neurology, Institut de Malalties del Sistema Nerviós, Hospital Clínic, IDIBAPS, University of Barcelona, Barcelona, Spain</affiliation><role><roleTerm type="text">author</roleTerm></role></name><typeOfResource>text</typeOfResource><genre authority="originalCategForm">article</genre><originInfo><publisher>Wiley Subscription Services, Inc., A Wiley Company</publisher><place><placeTerm type="text">Hoboken</placeTerm></place><dateIssued encoding="w3cdtf">2004-12</dateIssued><dateCaptured encoding="w3cdtf">2003-10-28</dateCaptured><dateValid encoding="w3cdtf">2004-03-16</dateValid><copyrightDate encoding="w3cdtf">2004</copyrightDate></originInfo><language><languageTerm type="code" authority="rfc3066">en</languageTerm><languageTerm type="code" authority="iso639-2b">eng</languageTerm></language><physicalDescription><internetMediaType>text/html</internetMediaType><extent unit="figures">1</extent><extent unit="tables">2</extent><extent unit="references">39</extent><extent unit="words">4442</extent></physicalDescription><abstract lang="en">Bilateral subthalamic deep brain stimulation (STN‐DBS) and continuous subcutaneous infusion of apomorphine (APM‐csi) can provide a comparable improvement on motor function in patients with advanced Parkinson's disease (PD), but the mechanisms by which both therapies exert their effects are different. We analyzed the cognitive effects of APM‐csi. We also compared neuropsychological effects induced by STN‐DBS and APM‐csi in advanced PD to ascertain the neuropsychological aspects relevant in determining the therapeutic procedure that is the most appropriate in a particular patient. We studied 9 patients treated with STN‐DBS and 7 patients with APM‐csi. Neuropsychological measures included Rey's Auditory‐Verbal Learning, Stroop, Trail Making, phonetic verbal fluency, and Judgment of Line Orientation tests. In the APM‐csi group, significant changes were not observed in the neuropsychological tests performance. By contrast, in the STN‐DBS group, moderate worsening was found in phonetic verbal fluency and Stroop Naming scores that was partially reversible at long‐term follow‐up and did not have consequences on regular activities. Consequently, these findings could be interpreted as being not relevant in deciding the most suitable treatment in a given patient. © 2004 Movement Disorder Society</abstract><note type="funding">Generalitat de Catalunya, Barcelona, Spain - No. 2001SGR00387; </note><note type="funding">European Neurological Society</note><subject lang="en"><genre>Keywords</genre><topic>Parkinson's disease</topic><topic>bilateral subthalamic deep brain stimulation</topic><topic>continuous subcutaneous infusion of apomorphine</topic><topic>cognition</topic><topic>prefrontal functions</topic></subject><relatedItem type="host"><titleInfo><title>Movement Disorders</title></titleInfo><titleInfo type="abbreviated"><title>Mov. Disord.</title></titleInfo><subject><genre>article category</genre><topic>Brief Report</topic></subject><identifier type="ISSN">0885-3185</identifier><identifier type="eISSN">1531-8257</identifier><identifier type="DOI">10.1002/(ISSN)1531-8257</identifier><identifier type="PublisherID">MDS</identifier><part><date>2004</date><detail type="volume"><caption>vol.</caption><number>19</number></detail><detail type="issue"><caption>no.</caption><number>12</number></detail><extent unit="pages"><start>1463</start><end>1469</end><total>7</total></extent></part></relatedItem><identifier type="istex">A4291B57194D36B638D5FCE9EFD0C151E0450713</identifier><identifier type="DOI">10.1002/mds.20237</identifier><identifier type="ArticleID">MDS20237</identifier><accessCondition type="use and reproduction" contentType="copyright">Copyright © 2004 Movement Disorder Society</accessCondition><recordInfo><recordOrigin>Wiley Subscription Services, Inc., A Wiley Company</recordOrigin><recordContentSource>WILEY</recordContentSource></recordInfo></mods></metadata><serie></serie></istex></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Wicri/Santé/explor/MovDisordV3/Data/Istex/Corpus
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 001248 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Istex/Corpus/biblio.hfd -nk 001248 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Wicri/Santé
|area= MovDisordV3
|flux= Istex
|étape= Corpus
|type= RBID
|clé= ISTEX:A4291B57194D36B638D5FCE9EFD0C151E0450713
|texte= Comparative cognitive effects of bilateral subthalamic stimulation and subcutaneous continuous infusion of apomorphine in Parkinson's disease
}}
| This area was generated with Dilib version V0.6.23. |  |